Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceutical Industries Ltd. announced results from a post hoc analysis of a long-term study on AJOVY® (fremanezumab-vfrm) for chronic and episodic migraine treatment. The analysis involved 1,043 patients, comparing migraine days during different dosing regimens. Findings showed no significant variation in migraine days between initial and final weeks of dosing. The mean weekly migraine days were 4.0 for chronic migraine and 2.3 for episodic migraine at baseline. No new safety signals were identified, and AJOVY remains the only long-acting anti-CGRP injection approved for both quarterly and monthly dosing.
Teva Pharmaceuticals USA has launched the FDA-approved generic versions of TRUVADA® and ATRIPLA® tablets, marking a significant step in increasing access to HIV treatments. These generics complement Teva's portfolio of over 10 HIV-related medications on the WHO's Essential Medicines list. The new generics provide vital options for the 1.2 million individuals living with HIV-1 in the U.S., as well as addressing the global shortfall of 12.6 million people without access to treatment. The wholesale acquisition cost is set at $48.51 per tablet for Emtricitabine/Tenofovir and $78.86 for the combination tablet.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its third quarter financial results on November 5, 2020, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Participants can join by dialing specified numbers, with a passcode of 7275239. A replay will be available within 24 hours. Teva is a global leader in generic and specialty medicines with over 3,500 products, servicing around 200 million daily users worldwide. The company emphasizes that this release may include forward-looking statements subject to risks and uncertainties.